Exploring Longevity Drugs in an Era of Slumping Investments and Rising Doubt

Venture capitalists have put the brakes on investments in longevity-related interventions over the past few years, yet experts predict new drug approvals will spur a funding surge.

investments-1

INVESTMENTS (1)

Despite slumping investments in longevity-related biotech companies over the last few years, experts predict a funding surge as new therapies get closer to approval.

Industry

Learning from Incredibly Resilient Creatures to Develop Anti-Aging Drugs

Dr. Ashley Zehnder, CEO of FaunaBio, an aging research biotech company, learns from long-lived animals to develop drugs against age-related diseases.

groundsquirrel

GROUNDSQUIRREL

(A 13-lined ground squirrel | Carnegie Museum of Natural History)

FaunaBio CEO and veterinarian scientist Dr. Ashley Zehnder shares how she utilizes gene activity profiles from long-lived hibernating mammals to develop drugs against human age-related diseases.

Meet the Largest Platform in the US Providing Longevity and Healthspan Consultation

CEO Dugal Bain-Kim provides insight into the Lifeforce program, administering longevity-focused blood tests once every three months along with healthspan-oriented consultations with physicians.

bain-kim

Bain-Kim

(Lifeforce CEO Dugal Bain-Kim | Built in LA)

Providing the largest longevity platform in the US where clients can gain telehealth advising from longevity experts, Lifeforce improves quality of life in the first three months for 85% of clientele.

By 2024, SirTLab aims to begin human testing of therapies that activate SIRT6, an enzyme shown to extend the lifespan of mice. 


human_sirt6_protein

Human_Sirt6_protein

Depiction of SIRT6 enzyme bound to the senolytic quercetin (blue & red balls) and ADP-ribose (green & red balls) | Wikipedia

Backed by the largest-ever individual investment towards a longevity startup from OpenAI CEO Sam Altman, Retro Biosciences will begin to tackle aging via cellular reprogramming, autophagy, and plasma-inspired therapeutics.   

gettyimages-1178810699

GettyImages-1178810699

Investor and OpenAI CEO Sam Altman | MIT Technology Review  

Seragon Releases Advanced Aging Intervention Nutraceutical RESTORIN

Seragon Biosciences has finally delivered its senolytic NAD+-boosting nutraceutical RESTORIN that combines the most advanced longevity technologies from Harvard University, Mayo Clinic and Scripps Research.

restorin-2

RESTORIN

The biopharma company Seragon launches an advanced anti-aging nutraceutical RESTORIN based on increasing NAD+ levels and senolytics that eliminate aged cells that cause tissue decline.

New Anti-Aging Supplement Mitopure

Using a novel anti-aging supplement, endorsed by Elon Musk’s mother, researchers characterize the microbiome of healthy individuals and replenish a longevity-linked metabolite called urolithin A. 


Exploring Longevity Drugs in an Era of Slumping Investments and Rising Doubt

Learning from Incredibly Resilient Creatures to Develop Anti-Aging Drugs

Meet the Latest Platform in the US Providing Longevity and Healthspan Consultation — Lifeforce

Biotech Startup SirTLab Prepares for Groundbreaking Human Trials of SIRT6-Boosting Therapy

ChatGPT Founder Sam Altman’s New Startup Retro Biosciences Aims to Reverse Aging

Seragon Releases Advanced Aging Intervention Nutraceutical RESTORIN

New Anti-Aging Supplement Mitopure Promotes Microbiome Health